Bluetooth Device Enables Remote Glucose Monitoring

A novel diabetes management platform can sync readings from over 30 blood glucose meters to supported Apple and Android devices.

The Glooko MeterSync Blue is a software as a service (SaaS) remote monitoring and population management platform that uses Bluetooth technology to provide health systems and payer groups the ability to more cost-effectively enroll diabetes patients into remote monitoring programs. With the MeterSync Blue, patients do not need to switch to costly, wireless-enabled, blood glucose meters developed specifically for telemedicine. Instead, health systems and payer groups can leverage the tens of millions of meters already deployed to patients worldwide.


The MeterSync Blue facilitates remote monitoring via the Glooko Population Tracker, which delivers pattern recognition algorithms and flags for care managers to easily identify patients experiencing potentially harmful amounts of hyperglycemic or hypoglycemic events in between clinic visits. By allowing patients to wirelessly sync their blood glucose reading after testing, the device opens the door for Glooko, in collaboration with health systems and payers, to deliver more real-time reminders and recommendations to patients with diabetes.

Cloud-based technology, mobile apps, and the MyGlooko secure web view allow users to email, print, or fax standardized reports to the healthcare team, including blood glucose averages, statistics, and graphs. The SaaS also hosts a food database with over 200,000 items from popular restaurants and grocery stores, and also integrates with popular food apps. Carbohydrate intake is chronologically associated with blood glucose data for better pattern recognition. The Glooko MeterSync Blue and apps are products of Glooko (Palo Alto, CA, USA).

“I am looking forward to using Glooko MeterSync Blue, which should make the platform more valuable by ensuring that patients can more seamlessly share their data with me between visits, particularly those at higher risk, including women during pregnancy and poorly controlled patients initiating treatment with insulin,” said endocrinologist Prof. Zachary Bloomgarden, MD, of Mt. Sinai Medical Center (New York, NY, USA). “It should also help with patients who are not at high risk but for whom the ability to review home glucose monitoring results will improve adherence to the increasingly complex regimens of modern diabetes management.”

Related Links:
Glooko